India, June 30 -- image credit- shutterstock

The patent war can become uglier at times and the pharma industry is no exception to this. Indian and MNC pharma companies are at loggerheads when it comes to global patent disputes. That Indians get affordable and accessible medicines is what the Government of India prioritises. However, MNC pharma companies want to dominate the market armed with patents.

The global pharmaceutical industry is bracing itself for the upcoming patent cliff which is touted to put an estimated $236 billion in drug sales in jeopardy for the innovator companies. Between 2025 and 2030, the patents on a number of blockbuster drugs spanning therapeutic areas including diabetes, cardiovascular, oncology immunology, and...